DD207220A5 - Verfahren zur herstellung von fuer einen mikroorganismus heterologem protein - Google Patents

Verfahren zur herstellung von fuer einen mikroorganismus heterologem protein Download PDF

Info

Publication number: DD207220A5
Authority: DD; German Democratic Republic
Prior art keywords: yeast; protein; ecori; fragment; gene
Prior art date: 1982-03-08

Application number

DD83248613A

Other languages

German (de)

English (en)

Inventor

Ronald A Hitzeman

David W-H Leung

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-08

Filing date

1983-03-08

Publication date

1984-02-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26998782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD207220(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-03-08 Application filed by Genentech Inc filed Critical Genentech Inc

1984-02-22 Publication of DD207220A5 publication Critical patent/DD207220A5/de

Links

108090000623 proteins and genes Proteins 0.000 title claims description 124
102000004169 proteins and genes Human genes 0.000 title claims description 73
238000000034 method Methods 0.000 title claims description 42
238000004519 manufacturing process Methods 0.000 title claims description 6
244000005700 microbiome Species 0.000 title 1
240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 112
230000028327 secretion Effects 0.000 claims abstract description 29
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 22
229920001184 polypeptide Polymers 0.000 claims abstract description 21
238000012545 processing Methods 0.000 claims abstract description 21
108010050904 Interferons Proteins 0.000 claims description 53
102000014150 Interferons Human genes 0.000 claims description 45
229940079322 interferon Drugs 0.000 claims description 34
230000008569 process Effects 0.000 claims description 12
108010047761 Interferon-alpha Proteins 0.000 claims description 7
102000006992 Interferon-alpha Human genes 0.000 claims description 6
239000001963 growth medium Substances 0.000 claims description 5
210000000265 leukocyte Anatomy 0.000 claims description 3
235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 8
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
108020004511 Recombinant DNA Proteins 0.000 abstract description 4
238000005516 engineering process Methods 0.000 abstract description 3
239000012634 fragment Substances 0.000 description 96
235000018102 proteins Nutrition 0.000 description 64
210000004027 cell Anatomy 0.000 description 62
239000013612 plasmid Substances 0.000 description 53
108020004414 DNA Proteins 0.000 description 45
230000000694 effects Effects 0.000 description 35
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
239000000047 product Substances 0.000 description 25
239000002609 medium Substances 0.000 description 24
238000010276 construction Methods 0.000 description 23
108010000521 Human Growth Hormone Proteins 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 22
210000002421 cell wall Anatomy 0.000 description 22
239000000499 gel Substances 0.000 description 22
150000001413 amino acids Chemical class 0.000 description 21
230000012010 growth Effects 0.000 description 20
102000002265 Human Growth Hormone Human genes 0.000 description 19
102100040019 Interferon alpha-1/13 Human genes 0.000 description 19
239000000854 Human Growth Hormone Substances 0.000 description 18
239000000203 mixture Substances 0.000 description 18
241000588724 Escherichia coli Species 0.000 description 16
108010078049 Interferon alpha-2 Proteins 0.000 description 16
102100040018 Interferon alpha-2 Human genes 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
239000000243 solution Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
108091026890 Coding region Proteins 0.000 description 12
108010076504 Protein Sorting Signals Proteins 0.000 description 11
239000002299 complementary DNA Substances 0.000 description 11
239000013598 vector Substances 0.000 description 11
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000000872 buffer Substances 0.000 description 10
230000029087 digestion Effects 0.000 description 10
239000000284 extract Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
238000000855 fermentation Methods 0.000 description 9
230000004151 fermentation Effects 0.000 description 9
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
229940047124 interferons Drugs 0.000 description 9
239000000600 sorbitol Substances 0.000 description 9
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 8
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
108091081024 Start codon Proteins 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
229920001817 Agar Polymers 0.000 description 7
230000005526 G1 to G0 transition Effects 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
239000008272 agar Substances 0.000 description 7
239000011324 bead Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
239000011521 glass Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000007017 scission Effects 0.000 description 7
238000012163 sequencing technique Methods 0.000 description 7
230000009466 transformation Effects 0.000 description 7
101150028074 2 gene Proteins 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
102000004594 DNA Polymerase I Human genes 0.000 description 6
108010017826 DNA Polymerase I Proteins 0.000 description 6
108010074328 Interferon-gamma Proteins 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
230000003248 secreting effect Effects 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 5
125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
238000012300 Sequence Analysis Methods 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
238000004166 bioassay Methods 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
229960000789 guanidine hydrochloride Drugs 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
210000005253 yeast cell Anatomy 0.000 description 5
101150084750 1 gene Proteins 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000000120 cytopathologic effect Effects 0.000 description 4
239000013613 expression plasmid Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
230000037361 pathway Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
241000894007 species Species 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
230000035899 viability Effects 0.000 description 4
239000012138 yeast extract Substances 0.000 description 4
108020005029 5' Flanking Region Proteins 0.000 description 3
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
238000010268 HPLC based assay Methods 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
108091092724 Noncoding DNA Proteins 0.000 description 3
101150006914 TRP1 gene Proteins 0.000 description 3
239000004098 Tetracycline Substances 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
230000016396 cytokine production Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
229960002180 tetracycline Drugs 0.000 description 3
229930101283 tetracycline Natural products 0.000 description 3
235000019364 tetracycline Nutrition 0.000 description 3
150000003522 tetracyclines Chemical class 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
HRTNVZOWEFVIGJ-UHFFFAOYSA-N 2-anilino-4h-1,3-thiazol-5-one Chemical class S1C(=O)CN=C1NC1=CC=CC=C1 HRTNVZOWEFVIGJ-UHFFFAOYSA-N 0.000 description 2
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
230000007023 DNA restriction-modification system Effects 0.000 description 2
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
108010058643 Fungal Proteins Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000004091 panning Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
101150047627 pgk gene Proteins 0.000 description 2
QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000000734 protein sequencing Methods 0.000 description 2
239000012429 reaction media Substances 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
108010082737 zymolyase Proteins 0.000 description 2
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
ZZRIQDWDJVLELF-UHFFFAOYSA-N 3-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1C1=CC=CC=C1 ZZRIQDWDJVLELF-UHFFFAOYSA-N 0.000 description 1
GVUOPSNMFBICMM-UHFFFAOYSA-N 5-bromo-6-morpholin-4-yl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC(O)=C(Br)C(N2CCOCC2)=N1 GVUOPSNMFBICMM-UHFFFAOYSA-N 0.000 description 1
101100452755 Arabidopsis thaliana I-2 gene Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
101710089384 Extracellular protease Proteins 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241001446459 Heia Species 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
101710096444 Killer toxin Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710188313 Protein U Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
101150087698 alpha gene Proteins 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
101150067977 ap gene Proteins 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
238000009835 boiling Methods 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000005868 electrolysis reaction Methods 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
-1 nucleoside triphosphates Chemical class 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229940117953 phenylisothiocyanate Drugs 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
101150061147 preA gene Proteins 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000009987 spinning Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/30—Signal or leader sequence

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Mycology (AREA)
Endocrinology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Treatment And Processing Of Natural Fur Or Leather (AREA)
Lubricants (AREA)

DD83248613A 1982-03-08 1983-03-08 Verfahren zur herstellung von fuer einen mikroorganismus heterologem protein DD207220A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35529782A	1982-03-08	1982-03-08
US06/438,236 US4775622A (en)	1982-03-08	1982-11-01	Expression, processing and secretion of heterologous protein by yeast

Publications (1)

Publication Number	Publication Date
DD207220A5 true DD207220A5 (de)	1984-02-22

Family

ID=26998782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD83248613A DD207220A5 (de)	1982-03-08	1983-03-08	Verfahren zur herstellung von fuer einen mikroorganismus heterologem protein

Country Status (28)

Country	Link
US (1)	US4775622A (no)
EP (1)	EP0088632B1 (no)
JP (2)	JPH0829111B2 (no)
AU (1)	AU574323B2 (no)
BG (1)	BG46159A3 (no)
BR (1)	BR8301150A (no)
CZ (1)	CZ282905B6 (no)
DD (1)	DD207220A5 (no)
DE (2)	DE3308215C2 (no)
DK (1)	DK163932C (no)
DZ (1)	DZ513A1 (no)
ES (1)	ES520416A0 (no)
FI (1)	FI830774L (no)
FR (1)	FR2523152B1 (no)
GB (1)	GB2116567B (no)
GR (1)	GR78506B (no)
IE (1)	IE55743B1 (no)
IL (1)	IL68058A (no)
MX (1)	MX163813B (no)
NO (1)	NO830780L (no)
NZ (1)	NZ203494A (no)
OA (1)	OA07338A (no)
PH (1)	PH24804A (no)
PL (1)	PL153724B1 (no)
PT (1)	PT76360B (no)
RO (1)	RO88582A (no)
YU (1)	YU46723B (no)
ZW (1)	ZW6283A1 (no)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5196194A (en) *	1979-05-24	1993-03-23	The Regents Of The University Of California	Vaccines containing Hepatitis B S-protein
DE3176404D1 (en) *	1980-04-22	1987-10-08	Pasteur Institut	Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
US4769238A (en)	1981-08-04	1988-09-06	The Regents Of The University Of California	Synthesis of human virus antigens by yeast
JPS58146281A (ja) *	1981-10-19	1983-08-31	Suntory Ltd	酵母細胞の形質転換法
US4943529A (en) *	1982-05-19	1990-07-24	Gist-Brocades Nv	Kluyveromyces as a host strain
AU577259B2 (en) *	1982-08-13	1988-09-22	Zymogenetics Inc.	Glycolytic promters for regulated protein expression protease inhibitor
DK55685A (da) *	1985-02-07	1986-08-08	Nordisk Gentofte	Enzym eller enzymkompleks med proteolytisk aktivitet
US5618697A (en) *	1982-12-10	1997-04-08	Novo Nordisk A/S	Process for preparing a desired protein
EP0116201B1 (en) *	1983-01-12	1992-04-22	Chiron Corporation	Secretory expression in eukaryotes
NZ207925A (en) *	1983-04-25	1988-05-30	Genentech Inc	Yeast expression vehicle consisting of a yeast promoter and signal peptide encoding region linked to a heterologus peptide coding region; expression and culture
US7198919B1 (en)	1983-04-25	2007-04-03	Genentech, Inc.	Use of alpha factor sequences in yeast expression systems
US4859600A (en) *	1983-04-25	1989-08-22	Genentech, Inc.	Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) *	1983-04-25	1988-07-05	Genentech, Inc.	Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4870008A (en) *	1983-08-12	1989-09-26	Chiron Corporation	Secretory expression in eukaryotes
US5639639A (en) *	1983-11-02	1997-06-17	Genzyme Corporation	Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
DE3479520D1 (en) *	1983-11-21	1989-09-28	Ciba Geigy Ag	Synthesis of tissue plasminogen activator(tpa) by yeast
PH23920A (en) *	1983-12-20	1990-01-23	Cetus Corp	Glucoamylase cdna
FI841500A0 (fi) *	1984-04-13	1984-04-13	Valtion Teknillinen	Foerfarande foer uppbygnande av cellulolytiska jaeststammar.
US7273695B1 (en)	1984-10-31	2007-09-25	Novartis Vaccines And Diagnostics, Inc.	HIV immunoassays using synthetic envelope polypeptides
CA1341423C (en)	1984-10-31	2003-03-04	Paul A. Luciw	Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US7393949B1 (en)	1987-12-24	2008-07-01	Novartis Vaccines And Diagnostics, Inc.	Human immunodeficiency virus (HIV) nucleotide sequences
US7285271B1 (en)	1984-10-31	2007-10-23	Novartis Vaccines And Diagnostics, Inc.	Antigenic composition comprising an HIV gag or env polypeptide
ATE88754T1 (de) *	1984-12-06	1993-05-15	Fina Research	Transformierte hefen die lysozym produzieren, fuer diese transformation zu verwendende plasmide und deren verwendung.
US4902620A (en) *	1985-04-25	1990-02-20	Eli Lilly And Company	Novel DNA for expression of delta-aminolevulinic acid synthetase and related method
WO1986007093A1 (en) *	1985-05-29	1986-12-04	The Green Cross Corporation	Process for preparing heterogenic protein
US5164485A (en) *	1985-08-20	1992-11-17	Takeda Chemical Industries, Ltd.	Modified hepatitis B virus surface antigen P31 and production thereof
EP0625577A1 (en) *	1985-08-29	1994-11-23	Genencor International, Inc.	Heterologous polypeptides expressed in filamentous fungi, processes for their preparation, and vectors for their preparation
JPS62175183A (ja) *	1985-08-29	1987-07-31	ジエネンコ−　インコ−ポレ−テツド	繊維状菌類中に発現する異種ポリペプチドとその製造方法及びその製造のためのベクタ−
US4937189A (en) *	1985-10-18	1990-06-26	Pfizer Inc.	Expression and secretion of heterologous proteins by Yarrowia lipolytica transformants
CA1295567C (en) *	1988-07-25	1992-02-11	Lawrence T. Malek	Expression system for the secretion of bioactive human granulocyte, macrophage-colony stimulating factor (gm-csf) and other heterologous proteins from streptomyces
GB8530631D0 (en)	1985-12-12	1986-01-22	Ciba Geigy Ag	Thrombin inhibitors
US5024941A (en) *	1985-12-18	1991-06-18	Biotechnica International, Inc.	Expression and secretion vector for yeast containing a glucoamylase signal sequence
US4935349A (en) *	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
US5536661A (en) *	1987-03-10	1996-07-16	Novo Nordisk A/S	Process for the production of protein products in aspergillus
US5766912A (en)	1986-03-17	1998-06-16	Novo Nordisk A/S	Humicola lipase produced in aspergillus
FR2599753B1 (fr) *	1986-06-05	1989-12-08	Sanofi Sa	Sequence d'adn composite et son application pour la production de l'hormone de croissance
GB8615701D0 (en) *	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
JPH0616716B2 (ja) *	1986-10-14	1994-03-09	塩野義製薬株式会社	酵母におけるヒトｐｓｔｉの製造法
MY103358A (en) *	1987-04-15	1993-06-30	Novartis Ag	Process for the production of protiens.
US5610034A (en) *	1987-04-29	1997-03-11	Alko Group Ltd.	Immunoglobulin production by trichoderma
JP2791418B2 (ja) *	1987-12-02	1998-08-27	株式会社ミドリ十字	異種蛋白質の製造方法、組換えｄｎａ、形質転換体
CA1340772C (en) *	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
JPH01240191A (ja) *	1988-02-16	1989-09-25	Green Cross Corp:The	酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
US5149544A (en) *	1989-11-13	1992-09-22	Research Corporation Technologies, Inc.	Method of inhibiting progenitor cell proliferation
US6172039B1 (en)	1990-04-16	2001-01-09	Apex Bioscience, Inc.	Expression of recombinant hemoglobin and hemoglobin variants in yeast
IE20020110A1 (en) *	1990-09-13	2003-05-28	Univ Duke	Expression of G Protein Coupled Receptors in Yeast
AU8740491A (en) *	1990-09-28	1992-04-28	Protein Engineering Corporation	Proteinaceous anti-dental plaque agents
US5364930A (en) *	1990-10-16	1994-11-15	Northwestern University	Synthetic C1q peptide fragments
US5932483A (en) *	1990-10-16	1999-08-03	Northwestern University	Synthetic peptide and its uses
FR2669931B1 (fr) *	1990-11-29	1995-03-31	Transgene	Nouveaux variants derives des interferons-alpha et leur procede de production.
JP3366947B2 (ja) *	1990-11-29	2003-01-14	アンスティテュナシオナルドラルシェルシュアグロノミクーイ．エン．エル．アー．	タイプ１インターフェロン由来の新規変異体、それらの製造方法及びそれらの適用
CA2058820C (en) *	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5330901A (en) *	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5538863A (en) *	1993-07-01	1996-07-23	Immunex Corporation	Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
US6500645B1 (en)	1994-06-17	2002-12-31	Novo Nordisk A/S	N-terminally extended proteins expressed in yeast
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
JP3763924B2 (ja) *	1997-03-17	2006-04-05	フクダ電子株式会社	超音波診断装置
US6265186B1 (en)	1997-04-11	2001-07-24	Dsm N.V.	Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
AU7466998A (en)	1997-04-14	1998-11-11	Byron E. Anderson	Method and material for inhibiting complement
FR2768743B1 (fr)	1997-09-23	2001-09-14	Bio Merieux	Procede de lyse de micro-organisme
GB2338236B (en)	1998-06-13	2003-04-09	Aea Technology Plc	Microbiological cell processing
US6268178B1 (en)	1999-05-25	2001-07-31	Phage Biotechnology Corp.	Phage-dependent super-production of biologically active protein and peptides
US6890730B1 (en)	1999-12-10	2005-05-10	The Salk Institute	Sequence and method for increasing protein expression in cellular expression systems
CA2747325A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US6358733B1 (en)	2000-05-19	2002-03-19	Apolife, Inc.	Expression of heterologous multi-domain proteins in yeast
US7449308B2 (en) *	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) *	2000-06-28	2011-01-04	Glycofi, Inc.	Production of sialylated N-glycans in lower eukaryotes
ATE440959T1 (de)	2000-06-28	2009-09-15	Glycofi Inc	Verfahren für die herstellung modifizierter glykoproteine
US7598055B2 (en)	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) *	2000-06-28	2014-04-15	Glycofi, Inc.	Production of modified glycoproteins having multiple antennary structures
US7625756B2 (en)	2000-06-28	2009-12-01	GycoFi, Inc.	Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
AU2002225681A1 (en) *	2000-11-15	2002-05-27	Globe Immune, Inc.	Yeast-dentritic cell vaccines and uses thereof
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en) *	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2484556A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2471363C (en)	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2004022593A2 (en) *	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP2630969B1 (en) *	2002-12-16	2018-04-11	GlobeImmune, Inc.	Yeast-based vaccines as immunotherapy
US7439042B2 (en) *	2002-12-16	2008-10-21	Globeimmune, Inc.	Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) *	2002-12-16	2013-01-01	Globeimmune, Inc.	Yeast-based vaccines as immunotherapy
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
US7332299B2 (en) *	2003-02-20	2008-02-19	Glycofi, Inc.	Endomannosidases in the modification of glycoproteins in eukaryotes
WO2005014825A2 (en)	2003-08-08	2005-02-17	Arriva Pharmaceuticals, Inc.	Methods of protein production in yeast
WO2005040395A1 (en) *	2003-10-22	2005-05-06	Keck Graduate Institute	Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
SI1684719T1 (sl) *	2003-11-14	2012-07-31	Baxter Int	Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
JP2008500275A (ja) *	2003-12-31	2008-01-10	セントカー・インコーポレーテツド	Ｎ末端の遊離チオールを有する新規な組み換えタンパク質
DE602005013912D1 (de)	2004-01-20	2009-05-28	Chemo Sero Therapeut Res Inst	Verfahren zur herstellung von humanserumalbumin durch wärmebehandlung in gegenwart von zweiwertigem kation
CN102614510A (zh) *	2004-10-18	2012-08-01	全球免疫股份有限公司	基于酵母的对慢性丙型肝炎感染的治疗
US7998930B2 (en)	2004-11-04	2011-08-16	Hanall Biopharma Co., Ltd.	Modified growth hormones
US20070105768A1 (en) *	2004-11-10	2007-05-10	Rajiv Nayar	Dry recombinant human alpha 1-antitrypsin formulation
KR20080043775A (ko) *	2005-07-11	2008-05-19	글로브이뮨	표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en)	2005-12-13	2007-07-26	Mycologics,Inc.	Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
JP2009531068A (ja) *	2006-03-27	2009-09-03	グローブイミューン，インコーポレイテッド	Ｒａｓ変異並びにこれに関連する組成物及び方法
JP2008174489A (ja) *	2007-01-18	2008-07-31	Nitto Denko Corp	微生物とペプチド性薬物を含む新規製剤
PL2121013T3 (pl) *	2007-02-02	2015-05-29	Globeimmune Inc	Sposoby wytwarzania szczepionek na bazie drożdży
BRPI0809247A2 (pt) *	2007-03-19	2014-09-09	Globeimmune Inc	Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer.
WO2010033841A1 (en)	2008-09-19	2010-03-25	Globeimmune, Inc.	Immunotherapy for chronic hepatitis c virus infection
KR102019728B1 (ko)	2009-04-17	2019-09-09	글로브이뮨	암에 대한 병용 면역요법 조성물 및 방법
AU2010291985B2 (en)	2009-09-14	2016-05-05	The Regents Of The University Of Colorado	Modulation of yeast-based immunotherapy products and responses
EP2651439B1 (en)	2010-12-17	2018-09-19	Globeimmune, Inc.	Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CA2827150C (en)	2011-02-12	2018-09-11	Globeimmune, Inc.	Yeast-based therapeutic for chronic hepatitis b infection
WO2012125998A1 (en)	2011-03-17	2012-09-20	Globeimmune, Inc.	Yeast-brachyury immunotherapeutic compositions
EA030381B1 (ru)	2011-06-14	2018-07-31	Глоубиммьюн, Инк.	Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта
KR102049928B1 (ko)	2011-08-17	2019-11-28	글로브이뮨	효모-muc1 면역요법 조성물 및 그 용도
SG11201408652SA (en)	2012-06-26	2015-01-29	Biodesix Inc	Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
LT2872644T (lt)	2012-07-12	2017-10-10	Uab Baltymas	Natyvių rekombinantinių sekretuojamų žmogaus endoplazminio tinklo šaperonų gamyba, panaudojant jų natyvias signalines sekas, mielių raiškos sistemose
EP2976100B1 (en)	2013-03-19	2020-07-01	Globeimmune, Inc.	Yeast-based immunotherapy for chordoma
TWI728239B (zh)	2013-03-26	2021-05-21	美商環球免疫公司	治療或預防人類免疫缺乏病毒感染之組合物及方法
US10226522B2 (en)	2013-08-30	2019-03-12	Globeimmune, Inc.	Compositions and methods for the treatment or prevention of tuberculosis
JP2017507182A (ja) *	2014-02-24	2017-03-16	ザ・ジョンズ・ホプキンス・ユニバーシティ	Ｔｍｅｍ１００ペプチド及びその変異体、並びに疾患又は状態の処置又は予防におけるそれらの使用
CA2948803A1 (en)	2014-04-11	2015-10-15	Globeimmune, Inc.	Yeast-based immunotherapy and type i interferon sensitivity
TWI748957B (zh)	2015-08-03	2021-12-11	美商環球免疫公司	經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
EP3793576A4 (en)	2018-05-15	2022-04-06	Globeimmune, Inc.	Lysates of recombinant yeast for inducing cellular immune responses
US12161777B2 (en)	2020-07-02	2024-12-10	Davol Inc.	Flowable hemostatic suspension
US11739166B2 (en)	2020-07-02	2023-08-29	Davol Inc.	Reactive polysaccharide-based hemostatic agent
MX2023007767A (es)	2020-12-28	2023-07-07	Davol Inc	Materiales hemostaticos secos en polvo reactivos que comprenden una proteina y un agente de entrelazado a base de polietilenglicol modificado multifuncional.
CN113549639B (zh) *	2021-07-21	2022-07-29	云南中烟工业有限责任公司	一种降低烟叶总蛋白及烟气苯酚含量的调控基因

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2441659A1 (fr) *	1978-11-14	1980-06-13	Anvar	Nouveaux plasmides hybrides et microorganismes les contenant
US4503035B1 (en)	1978-11-24	1996-03-19	Hoffmann La Roche	Protein purification process and product
GR68404B (no) *	1979-06-01	1981-12-29	Univ California
US4342832A (en) *	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
JPS5630925A (en) *	1979-08-21	1981-03-28	Sumitomo Chem Co Ltd	Purification of human growth hormone
US4443539A (en) *	1980-02-05	1984-04-17	The Upjohn Company	Process for preparing bovine growth hormone
GB2068969B (en) *	1980-02-05	1983-07-27	Upjohn Co	Gene expression
US4370417A (en) *	1980-04-03	1983-01-25	Abbott Laboratories	Recombinant deoxyribonucleic acid which codes for plasminogen activator
US4338397A (en) *	1980-04-11	1982-07-06	President And Fellows Of Harvard College	Mature protein synthesis
GB2079288B (en) *	1980-05-12	1984-05-16	Biogen Nv	Dna sequences recombinat dna molecules and processes for producing polypeptides with the specificity of foot and mouth disease viral antigens
CH657141A5 (de) *	1980-07-01	1986-08-15	Hoffmann La Roche	Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
IL63916A0 (en) *	1980-09-25	1981-12-31	Genentech Inc	Microbial production of human fibroblast interferon
US4506013A (en) *	1980-10-03	1985-03-19	Eli Lilly And Company	Stabilizing and selecting recombinant DNA host cells
US4456748A (en) *	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
US4414150A (en) *	1980-11-10	1983-11-08	Genentech, Inc.	Hybrid human leukocyte interferons
US4666847A (en) *	1981-01-16	1987-05-19	Collaborative Research, Inc.	Recombinant DNA means and method
NZ199722A (en) *	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS58996A (ja) *	1981-06-01	1983-01-06	ザ・ボ−ド・オブ・トラステイ−ズ・ミシガンステ−トユニバ−シテイ−	細菌中での牛成長ホルモン遺伝子のクロ−ン化
IE53517B1 (en) *	1981-06-17	1988-12-07	Celltech Ltd	Process for the production of a polypeptide
IE54046B1 (en) *	1981-08-25	1989-05-24	Celltech Ltd	Expression vectors
NZ201705A (en) *	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
US4546082A (en) *	1982-06-17	1985-10-08	Regents Of The Univ. Of California	E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins

1982
- 1982-11-01 US US06/438,236 patent/US4775622A/en not_active Expired - Lifetime
1983
- 1983-03-05 DZ DZ836783A patent/DZ513A1/fr active
- 1983-03-06 IL IL68058A patent/IL68058A/xx not_active IP Right Cessation
- 1983-03-07 BG BG060015A patent/BG46159A3/xx unknown
- 1983-03-07 NZ NZ203494A patent/NZ203494A/en unknown
- 1983-03-07 DK DK111283A patent/DK163932C/da not_active IP Right Cessation
- 1983-03-07 NO NO830780A patent/NO830780L/no unknown
- 1983-03-08 DD DD83248613A patent/DD207220A5/de unknown
- 1983-03-08 BR BR8301150A patent/BR8301150A/pt unknown
- 1983-03-08 ES ES520416A patent/ES520416A0/es active Granted
- 1983-03-08 OA OA57932A patent/OA07338A/xx unknown
- 1983-03-08 GR GR70725A patent/GR78506B/el unknown
- 1983-03-08 GB GB08306285A patent/GB2116567B/en not_active Expired
- 1983-03-08 YU YU55683A patent/YU46723B/sh unknown
- 1983-03-08 JP JP58038116A patent/JPH0829111B2/ja not_active Expired - Lifetime
- 1983-03-08 FR FR8303755A patent/FR2523152B1/fr not_active Expired
- 1983-03-08 IE IE498/83A patent/IE55743B1/en not_active IP Right Cessation
- 1983-03-08 ZW ZW62/83A patent/ZW6283A1/xx unknown
- 1983-03-08 PH PH28614A patent/PH24804A/en unknown
- 1983-03-08 MX MX196514A patent/MX163813B/es unknown
- 1983-03-08 FI FI830774A patent/FI830774L/fi not_active Application Discontinuation
- 1983-03-08 PL PL1983240927A patent/PL153724B1/pl unknown
- 1983-03-08 DE DE3308215A patent/DE3308215C2/de not_active Expired - Lifetime
- 1983-03-08 DE DE8383301269T patent/DE3382694T2/de not_active Expired - Lifetime
- 1983-03-08 EP EP83301269A patent/EP0088632B1/en not_active Revoked
- 1983-03-08 AU AU12152/83A patent/AU574323B2/en not_active Expired
- 1983-03-08 CZ CS831608A patent/CZ282905B6/cs not_active IP Right Cessation
- 1983-03-08 RO RO83110268A patent/RO88582A/ro unknown
- 1983-03-08 PT PT76360A patent/PT76360B/pt unknown
1993
- 1993-04-20 JP JP5093196A patent/JPH06181779A/ja active Pending

Also Published As

Publication number	Publication date
ES8500324A1 (es)	1984-11-01
IE55743B1 (en)	1991-01-02
YU46723B (sh)	1994-04-05
GB2116567B (en)	1986-01-02
AU574323B2 (en)	1988-07-07
EP0088632B1 (en)	1993-06-16
JPS58174396A (ja)	1983-10-13
FR2523152B1 (fr)	1985-08-23
PH24804A (en)	1990-10-30
DK111283A (da)	1983-10-28
DE3308215C2 (de)	1994-01-27
IE830498L (en)	1983-09-08
CZ160883A3 (en)	1997-07-16
FI830774A0 (fi)	1983-03-08
MX163813B (es)	1992-06-22
NO830780L (no)	1983-09-09
OA07338A (fr)	1984-08-31
DE3308215A1 (de)	1983-11-17
YU55683A (en)	1989-08-31
DK163932C (da)	1996-12-23
GB8306285D0 (en)	1983-04-13
ES520416A0 (es)	1984-11-01
EP0088632A2 (en)	1983-09-14
DK163932B (da)	1992-04-21
EP0088632A3 (en)	1984-06-20
ZW6283A1 (en)	1983-06-01
PL153724B1 (en)	1991-05-31
IL68058A (en)	1989-12-15
RO88582A (ro)	1986-02-28
NZ203494A (en)	1986-06-11
BR8301150A (pt)	1983-11-22
GR78506B (no)	1984-09-27
PL240927A1 (en)	1983-11-07
JPH0829111B2 (ja)	1996-03-27
CZ282905B6 (cs)	1997-11-12
PT76360A (en)	1983-04-01
JPH06181779A (ja)	1994-07-05
US4775622A (en)	1988-10-04
DK111283D0 (da)	1983-03-07
DE3382694T2 (de)	1993-09-23
AU1215283A (en)	1983-09-15
DE3382694D1 (de)	1993-07-22
BG46159A3 (en)	1989-10-16
GB2116567A (en)	1983-09-28
DZ513A1 (fr)	2004-09-13
FR2523152A1 (fr)	1983-09-16
PT76360B (en)	1986-02-12
FI830774L (fi)	1983-09-09
IL68058A0 (en)	1983-06-15

Publication	Publication Date	Title
DE3308215C2 (de)	1994-01-27	Expression, Processing und Sekretion von heterologem Protein durch Hefe
DE68927583T2 (de)	1997-07-10	Für menschliches Serum Albumin (HSA) kodierende DNA, Plasmide und Wirtzellen, die solche DNA enthalten sowie die Herstellung von HSA
DE3689846T2 (de)	1994-09-22	Erhöhte ausscheidung von heterologen proteinen durch wirtszellen durch verwendung von substituierten promotoren.
DE3280468T2 (de)	1995-12-07	Synthese von menschlichen Virusantigenen durch Hefe.
DE4226971C2 (de)	1997-01-16	Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
DE3881776T2 (de)	1993-11-18	DNS-Konstruktionen, enthaltend eine Kluyveromyces-alpha-Factor-Leadersequenz zur Leitung der Sekretion von heterologen Polypeptiden.
DE3486206T2 (de)	1994-02-03	Expressionssysteme für Hefe mit PyK-Promotoren enthaltenden Vektoren und Synthese von Fremdproteinen.
DE3885728T2 (de)	1994-03-10	Verbesserung der Expression und Sekretion heterologener Proteine in Hefe mittels trunkierter Sequenzen des Alpha-Faktor-Leaders.
DE3687878T2 (de)	1993-07-15	Expression und sekretion von heterologen proteinen durch transformanten von yarrowia lipolytica.
DE3884356T2 (de)	1994-03-10	Verfahren zur Herstellung von Fremdprotein in Hefe, Rekombinant DNS, Transformant.
EP0123544A2 (en)	1984-10-31	Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor
DD218118A5 (de)	1985-01-30	Verfahren zur herstellung eines hefe- oder nichthefepolypeptids
Ott et al.	1991	Cloning and expression in Saccharomyces cerevisiae of a synthetic gene for the type-I trophoblast interferon ovine trophoblast protein-1: purification and antiviral activity
CH656388A5 (de)	1986-06-30	Dns-sequenzen und rekombinante expressionsvektoren zur mikrobiellen herstellung von human-fibroblasten-interferon.
DE69027948T2 (de)	1997-01-30	Reinigung von rekombinantem, menschlichem Interleukin-3
US7198919B1 (en)	2007-04-03	Use of alpha factor sequences in yeast expression systems
DE3689918T2 (de)	1994-10-20	Verfahren zur Verwendung von BAR1 für die Fremdproteinsekretion.
DE3887425T2 (de)	1994-06-23	BAR1-Sekretions-Signal-Sequenz.
DE3687796T2 (de)	1993-06-09	Verkuerzter phosphoglycerat-kinase-promotor.
WO2000040727A2 (de)	2000-07-13	Rekombinanter wachstumsfaktor mit der biologischen aktivität eines g-csf (granulocyte colony stimulating factor)